Convertible ROS Nanocatalyst/Eliminator for Enhancing Tumor Radio-Immunotherapy and Relieving Radiation Enteritis

可转化ROS纳米催化剂/清除剂用于增强肿瘤放射免疫疗法和缓解放射性肠炎

阅读:1

Abstract

Radiation-induced damage to normal tissue seriously disrupts the execution of radiotherapy (RT) and therefore attenuates its efficacy. Exploring new strategies to enhance the efficacy and reduce toxicity of RT has great clinical importance. Here, a PD-L1 affibody (Z(PD-L1)) grafted Janus Ag/Ag(2)S nanoarchitectures is developed as "reactive oxygen species lever" to enhance radiocatalysis and relieve radiation enteritis. The nanoplatform can achieve abundant energy deposition in the form of high-energy electrons within tumors upon X-ray exposure. Subsequently, the transfer of electrons from Ag(2)S to Ag moiety enables effective electron-hole pair separation, which greatly improves the radiocatalysis efficiency in generating highly toxic hydroxyl radical (•OH). Due to the specific binding to tumor PD-L1, Z(PD-L1) endows this nanoplatform with efficient tumor targeting and meanwhile reduces immune suppression of T cells by achieving PD-1/PD-L1 blockade, intensifying RT-induced immunologic cell death. Notably, the presence of the Ag moiety allows the nanoplatform to act as an H(2)O(2) scavenger in intestinal tissues during metabolism, effectively relieving radiation enteritis. Moreover, systemic administration of the nanoplatform coupled with Mn-DOTA can guide RT timing selection by magnetic resonance imaging. Overall, this nanoplatform can substantially improve RT effectiveness with reduced radiation enteritis, demonstrating considerable potential in tumor RT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。